Skeletal myoblasts for cardiac repair.
Skeletal myoblasts for cardiac repair.
复制标题
DOI：
10.2217/rme.10.65
复制
发表时间：
2010-11
影响因子：
2.7
通讯作者：
Haider KH
中科院分区：
文献类型：
--
作者：
Durrani S;Konoplyannikov M;Ashraf M;Haider KH
干细胞通过补偿心肌损伤后的心肌细胞损失，为梗死心脏提供了另一种治疗性干预。在心脏中存在常驻干细胞和祖细胞群体，以及具有多能性标记物的遗传诱导的体细胞的核重编程是基于干细胞的再生医学中出现的新发展。然而，直到通过在体外和体内实验模型中的广泛实验建立这些细胞的安全性和可行性，骨骼肌来源的成肌细胞和骨髓细胞仍然是用于心肌再生和修复的最充分研究的供体细胞类型。本文根据已发表的实验和临床数据，对骨骼肌成肌细胞作为移植供体细胞进行了严格的审查，并深入讨论了骨骼肌成肌细胞为基础的治疗性干预在梗死心脏中增强心肌功能的优点和缺点。此外，还讨论了克服成肌细胞的成纤维性和移植后不能与宿主心肌细胞整合的问题的策略。
Stem cells provide an alternative curative intervention for the infarcted heart by compensating for the cardiomyocyte loss subsequent to myocardial injury. The presence of resident stem and progenitor cell populations in the heart, and nuclear reprogramming of somatic cells with genetic induction of pluripotency markers are the emerging new developments in stem cell-based regenerative medicine. However, until safety and feasibility of these cells are established by extensive experimentation in in vitro and in vivo experimental models, skeletal muscle-derived myoblasts, and bone marrow cells remain the most well-studied donor cell types for myocardial regeneration and repair. This article provides a critical review of skeletal myoblasts as donor cells for transplantation in the light of published experimental and clinical data, and indepth discussion of the advantages and disadvantages of skeletal myoblast-based therapeutic intervention for augmentation of myocardial function in the infarcted heart. Furthermore, strategies to overcome the problems of arrhythmogenicity and failure of the transplanted skeletal myoblasts to integrate with the host cardiomyocytes are discussed.